A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS

被引：4
|
作者：
DiNardo, Courtney D.
Kantarjian, Hagop M.
Ravandi, Farhad
Konopleva, Marina
Kadia, Tapan M.
Borthakur, Gautam
Daver, Naval G.
Durand, Mends
Rivera, Silvia
Quintas-Cardama, Alfonso
Garcia-Manero, Guillermo
Cortes, Jorge E.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.2698.2698
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2698
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS
    Mawad, Raya
    Becker, Pamela S.
    Hendrie, Paul
    Scott, Bart
    Wood, Brent L.
    Dean, Carol
    Sandhu, Vicky
    Deeg, Hans Joachim
    Walter, Roland
    Wang, Lixia
    Myint, Han
    Singer, Jack W.
    Estey, Elihu
    Pagel, John M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (02) : 238 - 245
  • [2] Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results
    Cortes, Jorge E.
    Smith, B. Douglas
    Wang, Eunice S.
    Merchant, Akil
    Oehler, Vivian G.
    Arellano, Martha
    DeAngelo, Daniel J.
    Pollyea, Daniel A.
    Sekeres, Mikkael A.
    Robak, Tadeusz
    Ma, Weidong Wendy
    Zeremski, Mirjana
    Shaik, M. Naveed
    Laird, A. Douglas
    O'Connell, Ashleigh
    Chan, Geoffrey
    Schroeder, Mark A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (11) : 1301 - 1310
  • [3] A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
    Mawad, Raya
    Becker, Pamela S.
    Hendrie, Paul C.
    Scott, Bart L.
    Wood, Brent L.
    Dean, Carol
    Sandhu, Vicky
    Deeg, H. Joachim
    Walter, Roland B.
    Wang, Lixia
    Singer, Jack
    Estey, Elihu H.
    Pagel, John
    BLOOD, 2014, 124 (21)
  • [4] A Phase II Study of Post-Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study
    Gardin, Claude
    Prebet, Thomas
    Bouabdallah, Krimo
    Caillot, Denis
    Guerci, Agnes
    Raffoux, Emmanuel
    Marolleau, Jean Pierre
    Pautas, Cecile
    Banos, Anne
    Himberlin, Chantal
    Taksin, Anne-Laure
    Pigneux, Arnaud
    Thomas, Xavier
    Jernival, Tony
    Vey, Norbert
    Dreyfus, Francois
    Chevret, Sylvie
    Dombret, Herve
    Fenaux, Pierre
    BLOOD, 2009, 114 (22) : 348 - 348
  • [5] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Daver, Naval Guastad
    Kantarjian, Hagop M.
    Pierce, Sherry
    Brandt, Mark
    Dinardo, Courtney Denton
    Pemmaraju, Naveen
    Vaughan, Kenneth
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan M.
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Invasive Fungal Infections in Patients with High-Risk MDS and AML Treated with Azacitidine
    Pomares, Helena
    Arnan, Montserrat
    Sanchez-Ortega, Isabel
    Sureda, Anna
    Duarte, Rafael F.
    BLOOD, 2015, 126 (23)
  • [7] INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH HIGH-RISK MDS AND AML TREATED WITH AZACITIDINE
    Pomares Marin, H.
    Arnan Sangerman, M.
    Sanchez-Ortega Sanchez, I.
    Duarte Palomino, R. D.
    LEUKEMIA RESEARCH, 2015, 39 : S145 - S146
  • [8] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [9] Geriatric assessment:: a prospective study in older patients with AML and high-risk MDS
    Deschler, B.
    Ihorst, G.
    Kuhn, M.
    Rueter, B.
    Luebbert, M.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 : S26 - S27
  • [10] Azacitidine (AZA) plus idarubicin (IDA) in untreated high-risk MDS - A GFM phase I/II study
    Ades, L.
    De Renzis, B.
    Jeddi, R.
    Delaunay, J.
    Braun, T.
    Hunault-Berger, M.
    Stamatoullas, A.
    Sanhes, L.
    Samey, B.
    Chermat, F.
    Meddeb, B.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2013, 37 : S13 - S13
12345